BioAtla is extending its runway beyond key clinical readouts in 1H 2026 by restructuring and realigning resources, which ...

Radiopharm Theranostics Limited targets oncology with radiotherapeutics like Lu-RAD204 for NSCLC. Key 2025 data signals ...

Drug development is coming back in vogue and this fund’s ‘full life cycle’ approach means it’s ready to capture the gains ...

Deloitte urged pharma executives to “be bold” in a new report tracking the top 20 pharmaceutical companies’ R&D performance.

SUZHOU, China, March 27, 2025 /PRNewswire/ -- CStone Pharmaceuticals ("CStone", HKEX: 2616), a biopharmaceutical company dedicated to developing innovative cancer therapies, today reported 2024 annual ...

Johnson & Johnson has been saying for some time that it thinks its combination of Rybrevant and Lazcluze is the best option for patients with EGFR-mutated non-small cell lung cancer (NSCLC) – and now ...

MacroGenics, Inc.’s MGNX share price has dipped by 12.85%, which has investors questioning if this is right time to buy.

The U.S. Food and Drug Administration (FDA) has approved a new class of antibiotics for treating uncomplicated urinary tract ...

As AbbVie accuses Genmab of unlawfully using proprietary ADC technology, find out about their collaboration and the dispute ...

ADC Therapeutics' primary focus is on the CD19-targeted antibody-drug conjugate Zynlonta. Read why ADCT stock is rated as a ...

The first RIPTAC has just hit the clinic. Learn about this new technology that is being developed by Halda Therapeutics.